Eckert & Ziegler SE
0NZY.L
London Stock Exchange15.38
EUR
+0.21
- -
Eckert & Ziegler SE
0NZY.L
(London Stock Exchange)
Recent
price
15.38
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Eckert & Ziegler SE Eckert & Ziegler SE is a Germany-based provider of isotope technology for medical, scientific, and industrial applications, with headquarters in Berlin and operations spanning Europe, North America, Asia-Pacific, and other regions. Founded in 1997 as a holding company, the group traces its roots to 1992 through predecessor entities like BEBIG GmbH and operates through two primary segments: Medical, which offers radiopharmaceuticals, radiochemicals, and contract manufacturing services for cancer diagnostics and therapy including brachytherapy solutions and radionuclide production such as lutetium-177 and actinium-225; and Isotope Products, which manufactures and distributes radiation sources, standards, and components for industrial radiometry, nuclear imaging, material testing, and scientific research. The company serves healthcare providers, pharmaceutical firms, research institutions, and industrial clients globally, with over 1,000 employees supporting production, development, and distribution from facilities including subsidiaries like Eckert & Ziegler Isotope Products in California and Eckert & Ziegler Radiopharma GmbH in Berlin. Recent developments include a November 2024 technology collaboration and license agreement with Telix Pharmaceuticals for cyclotron-based actinium-225 production to advance targeted alpha therapies; a March 2025 global supply agreement with AtomVie Global Radiopharma for non-carrier-added lutetium-177 chloride to bolster CDMO activities; an April 2024 partnership with RLS Radiopharmacies to expand gallium-68 radiopharmaceutical production; divestment of the HDR tumor irradiation division; acquisition of majority stake in PentixaPharm for drug development followed by its spin-off; and a change of legal form to Societas Europaea (SE).